Back

EHA 2021 - Annual Congress of the European Hematology Association (Virtual Meeting)

Jun 09 - Jun 17, 2021 | ViennaAustria

LARVOL is not affiliated with Annual Congress of the European Hematology Association (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Top Trials

Showing 398 abstracts linked to Trials

p301-6 (LB1900) - [VIRTUAL] FIRST INTERIM ANALYSIS OF ALPINE STUDY: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

  • Late-Breaking
15 Twitter Reactions

p302-4 (LB1901) - [VIRTUAL] OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

  • Late-Breaking
12 Twitter Reactions

EP786 - [VIRTUAL] KTE-X19 VERSUS STANDARD OF CARE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH BRUTON TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM EUROPE

  • E-Poster
10 Twitter Reactions

p205-4 (LB1904) - [VIRTUAL] A COMPARISON OF CLINICAL OUTCOMES FROM ZUMA-5 (AXICABTAGENE CILOLEUCEL) AND THE INTERNATIONAL SCHOLAR-5 EXTERNAL CONTROL COHORT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

  • Late-Breaking, Oral
10 Twitter Reactions

p302-5 (LB1902) - [VIRTUAL] FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY

  • Late-Breaking
8 Twitter Reactions

EP1015 - [VIRTUAL] EARLY INTENSIVE CONSOLIDATION WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

  • E-Poster
7 Twitter Reactions

p205-3 (LB1903) - [VIRTUAL] SAFETY AND EFFICACY OF CD37-TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND OTHER NON-HODGKIN’S B-CELL LYMPHOMAS – A PHASE 2 STUDY

  • Late-Breaking, Oral
3 Twitter Reactions